Literature DB >> 6468477

Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications.

J E Hodler, R L Galeazzi, B Frey, M Rudhardt, A J Seiler.   

Abstract

The pharmacokinetics of cefoperazone after i.p. and/or i.v. administration were studied in 12 CAPD patients. After i.v. injection, the plasma half-life was 2.65 +/- 0.4 h, the total clearance amounting to 70.1 +/- 19.2 ml/min. Peritoneal clearance was calculated to be 6.9 +/- 1 ml/min. After peritoneal instillation, the bioavailability was 63.9 +/- 5%. After repeated i.p. administration, no accumulation of the drug in the body was observed. Thus, cefoperazone can be safely administered for the treatment of peritonitis in CAPD patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6468477     DOI: 10.1007/bf00543494

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  Intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis.

Authors:  T E Wideröe; L C Smeby; K J Berg; S Jörstad; T M Svartås
Journal:  Kidney Int       Date:  1983-01       Impact factor: 10.612

2.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

3.  Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat.

Authors:  J Fabre; P Blanchard; M Rudhardt
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

  3 in total
  5 in total

1.  Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.

Authors:  C A Johnson; S W Zimmerman; D P Reitberg; T J Whall; J E Leggett; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

2.  Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vincon; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 5.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.